Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

Update

$Zura Bio (ZURA.US)$ Zura Bio Ltd: Tibulizumab (Zb-106) Was Well Tolerated and Neutralized Il-17a and Baff in a Phase 1 Study in Patients With Sjogren's Syndrome! Presents data at EULAR 2024
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
4
+0
Translate
Report
5641 Views
Comment
Sign in to post a comment